Current Therapeutics for COVID-19, What We Know about the Molecular Mechanism and Efficacy of Treatments for This Novel Virus.
Current Therapeutics for COVID-19, What We Know about the Molecular Mechanism and Efficacy of Treatments for This Novel Virus.
复制标题
当前COVID-19的治疗方法，我们对这种新型病毒的分子机制和治疗效果的了解。
DOI：
10.3390/ijms23147702
复制
发表时间：
2022-07-12
影响因子：
5.6
通讯作者：
中科院分区：
文献类型：
--
作者：
严重急性呼吸道综合征-冠状病毒2（SARS-CoV-2）在全球范围内造成了严重的发病率和死亡率。尽管过去的冠状病毒近年来已引起大规模流行，但在冠状病毒病19（COVID-19）大流行开始时，有效的治疗方法仍然有限。新型SARS-CoV-2病毒的出现和在地球仪中的快速传播需要快速开发治疗方法。鉴于过去两年出现的多种疗法以及围绕这些疗法疗效的数据演变，我们的目标是提供影响各种COVID-19疗法临床使用的主要临床试验的最新情况。本文综述了美国目前使用的治疗方法，并讨论了这些治疗方法靶向SARS-CoV-2病毒或COVID-19疾病过程的分子机制。PubMed和EMBASE被用来寻找评估各种COVID-19疗法疗效的试验。以不同的组合搜索关键词SARS-CoV-2、COVID-19以及本综述中包含的各种疗法的名称，以查找自COVID-19大流行爆发以来进行的大规模随机对照试验。目前，多种治疗方案已被批准用于治疗SARS-CoV-2和预防住院和门诊高风险个体的严重疾病。在严重疾病中，目前建议联合抗病毒和免疫调节治疗。此外，抗病毒药物在预防门诊患者的严重疾病和住院治疗方面也显示出了希望。最近，目前的治疗方法是针对SARS-CoV-2病毒的单克隆抗体的早期治疗。尽管如此，迄今为止还没有一种治疗方法可以作为确定的治愈方法，针对SARS-CoV-2病毒的疫苗仍然是我们防止进一步发病和死亡的最佳防御手段。
Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has caused significant morbidity and mortality worldwide. Though previous coronaviruses have caused substantial epidemics in recent years, effective therapies remained limited at the start of the Coronavirus disease 19 (COVID-19) pandemic. The emergence and rapid spread throughout the globe of the novel SARS-CoV-2 virus necessitated a rapid development of therapeutics. Given the multitude of therapies that have emerged over the last two years and the evolution of data surrounding the efficacy of these therapies, we aim to provide an update on the major clinical trials that influenced clinical utilization of various COVID-19 therapeutics. This review focuses on currently used therapies in the United States and discusses the molecular mechanisms by which these therapies target the SARS-CoV-2 virus or the COVID-19 disease process. PubMed and EMBASE were used to find trials assessing the efficacy of various COVID-19 therapies. The keywords SARS-CoV-2, COVID-19, and the names of the various therapies included in this review were searched in different combinations to find large-scale randomized controlled trials performed since the onset of the COVID-19 pandemic. Multiple therapeutic options are currently approved for the treatment of SARS-CoV-2 and prevention of severe disease in high-risk individuals in both in the inpatient and outpatient settings. In severe disease, a combination of antiviral and immunomodulatory treatments is currently recommended for treatment. Additionally, anti-viral agents have shown promise in preventing severe disease and hospitalization for those in the outpatient setting. More recently, current therapeutic approaches are directed toward early treatment with monoclonal antibodies directed against the SARS-CoV-2 virus. Despite this, no treatment to date serves as a definitive cure and vaccines against the SARS-CoV-2 virus remain our best defense to prevent further morbidity and mortality.
登录
查看更多内容
DOI：
10.1056/nejmoa2029849
发表时间：
2021-01-21
期刊：
The New England journal of medicine
影响因子：
--
作者：
Chen P;Nirula A;Heller B;Gottlieb RL;Boscia J;Morris J;Huhn G;Cardona J;Mocherla B;Stosor V;Shawa I;Adams AC;Van Naarden J;Custer KL;Shen L;Durante M;Oakley G;Schade AE;Sabo J;Patel DR;Klekotka P;Skovronsky DM;BLAZE-1 Investigators
通讯作者：
BLAZE-1 Investigators
影响因子：
4.6
作者：
Menestrina L;Cabrelle C;Recanatini M
通讯作者：
Recanatini M
DOI：
10.1056/nejmoa2102685
发表时间：
2021-10-07
期刊：
The New England journal of medicine
影响因子：
--
作者：
Dougan M;Nirula A;Azizad M;Mocherla B;Gottlieb RL;Chen P;Hebert C;Perry R;Boscia J;Heller B;Morris J;Crystal C;Igbinadolor A;Huhn G;Cardona J;Shawa I;Kumar P;Adams AC;Van Naarden J;Custer KL;Durante M;Oakley G;Schade AE;Holzer TR;Ebert PJ;Higgs RE;Kallewaard NL;Sabo J;Patel DR;Dabora MC;Klekotka P;Shen L;Skovronsky DM;BLAZE-1 Investigators
通讯作者：
BLAZE-1 Investigators
DOI：
10.1056/nejmoa2116846
发表时间：
2022-01-27
期刊：
The New England journal of medicine
影响因子：
--
作者：
Gottlieb RL;Vaca CE;Paredes R;Mera J;Webb BJ;Perez G;Oguchi G;Ryan P;Nielsen BU;Brown M;Hidalgo A;Sachdeva Y;Mittal S;Osiyemi O;Skarbinski J;Juneja K;Hyland RH;Osinusi A;Chen S;Camus G;Abdelghany M;Davies S;Behenna-Renton N;Duff F;Marty FM;Katz MJ;Ginde AA;Brown SM;Schiffer JT;Hill JA;GS-US-540-9012 (PINETREE) Investigators
通讯作者：
GS-US-540-9012 (PINETREE) Investigators
DOI：
10.1056/nejmoa2118542
发表时间：
2022-04-14
期刊：
The New England journal of medicine
影响因子：
--
作者：
Hammond J;Leister-Tebbe H;Gardner A;Abreu P;Bao W;Wisemandle W;Baniecki M;Hendrick VM;Damle B;Simón-Campos A;Pypstra R;Rusnak JM;EPIC-HR Investigators
通讯作者：
EPIC-HR Investigators